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Aims Remote monitoring of implantable cardioverter-defibrillators may improve clinical outcome. A recent meta-analysis
of three randomized controlled trials (TRUST, ECOST, IN-TIME) using a specific remote monitoring system with
daily transmissions [Biotronik Home Monitoring (HM)] demonstrated improved survival. We performed a patient-
level analysis to verify this result with appropriate time-to-event statistics and to investigate further clinical
endpoints.
...................................................................................................................................................................................................
Methods
and results
Individual data of the TRUST, ECOST, and IN-TIME patients were pooled to calculate absolute risks of endpoints
at 1-year follow-up for HM vs. conventional follow-up. All-cause mortality analysis involved all three trials (2405 pa-
tients). Other endpoints involved two trials, ECOST and IN-TIME (1078 patients), in which an independent blinded
endpoint committee adjudicated the underlying causes of hospitalizations and deaths. The absolute risk of death at
1 year was reduced by 1.9% in the HM group (95% CI: 0.1–3.8%; P = 0.037), equivalent to a risk ratio of 0.62. Also
the combined endpoint of all-cause mortality or hospitalization for worsening heart failure (WHF) was significantly
reduced (by 5.6%; P = 0.007; risk ratio 0.64). The composite endpoint of all-cause mortality or cardiovascular (CV)
hospitalization tended to be reduced by a similar degree (4.1%; P = 0.13; risk ratio 0.85) but without statistical
significance.
...................................................................................................................................................................................................
Conclusion In a pooled analysis of the three trials, HM reduced all-cause mortality and the composite endpoint of all-cause
mortality or WHF hospitalization. The similar magnitudes of absolute risk reductions for WHF and CV endpoints
suggest that the benefit of HM is driven by the prevention of heart failure exacerbation.
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The rapidly growing number of patients with implantable
cardioverter-defibrillators (ICDs) translates into increasing demand
for their regular follow-up.1,2 Remote ICD monitoring has been intro-
duced to improve clinical efficiency by reducing the need for conven-
tional in-office follow-up visits.2–9 Remote monitoring also affords the
chance to adjust clinical care after detecting a change in the patient’s
clinical condition or device malfunction, which may improve major
clinical outcomes such as death and hospitalization. This is still an ac-
tive area of research with inconsistent findings,2,7–14 as several non-
randomized clinical studies observed a considerable outcome benefit
of remote ICD monitoring, including all-cause mortality,10,14,15 and
randomized trials mostly reported neutral results.3,5,8,9,12
A meta-analysis of nine randomized controlled trials published by
Parthiban et al.13 in June 2015 suggested that remote ICD monitoring
does not improve all-cause mortality, cardiovascular (CV) mortality,
or overall hospitalization compared with conventional in-office fol-
low-up.13 Only one trial (IN-TIME) showed a significant positive ef-
fect of remote monitoring on the primary clinical outcome
(composite clinical score16) and on all-cause mortality.12,13 A signifi-
cant mortality reduction was also seen in pooled data for all trials
(TRUST, ECOST, IN-TIME) using a specific remote monitoring sys-
tem with daily verification of transmission [Biotronik Home
Monitoring (HM)].13 This observation warrants closer examination
and corroborates the suggestion that not all telemonitoring
approaches in heart failure are the same in practice and in their re-
sulting outcomes.17 Hence, system specific analyses may be prefer-
able to a global analysis combining systems with different operational
characteristics.
In the present meta-analysis, we combined individual data for the
TRUST,3 ECOST,5 and IN-TIME12 patients. The aim was to verify and
deepen the Parthiban meta-analysis in the part related to the remote
technology specialized for daily data transmission.13 We first verified
the survival finding by using time-to-event models instead of the
pooled odds ratio estimates,13 and subsequently investigated several
clinical endpoints combining cause-specific deaths and hospital-
izations in a way suitable to explore the mechanism of clinical benefit.
Methods
Trials included
We pooled patient-level data from the three trials identified by Parthiban
et al.13 as the only randomized controlled trials using specific remote
monitoring system with daily verification of transmission (Biotronik
Home Monitoring, Biotronik SE & Co. KG, Berlin, Germany), subse-
quently referred to as ‘HM’. In chronological order, TRUST (Lumos-T
safely reduces routine office device follow-up),3 ECOST (Effectiveness
and cost of ICDs follow-up schedule with telecardiology),5 and IN-TIME
(Influence of HM on mortality and morbidity in heart failure patients with
impaired left ventricular function)12 study investigators reported clinical
outcomes for HM vs. conventional in-office follow-up without HM in pa-
tients treated with ICDs or cardiac resynchronization therapy defibrilla-
tors (CRT-Ds). Table 1 compares trial characteristics.
The three trials had different primary objectives. TRUST (published in
2010) evaluated the safety of extended in-office follow-up intervals in the
HM arm during 15 months after ICD implantation.3 ECOST (2013) com-
pared major CV adverse events combined with all-cause death during 27
months after ICD implantation.5 IN-TIME (2014) focused on a composite
clinical score for heart failure (‘Packer score’),16 combining all-cause
death, overnight hospitalization for heart failure, change in New York
Heart Association (NYHA) class, and change in patient global self-
assessment. The number of patients with worsened composite clinical
score was compared for HM vs. conventional follow-up at 12 months
after ICD or CRT-D implantation.12,16
The regular in-office follow-up schedule was less intensive in the HM
than control arm in TRUST and ECOST, but equally intensive in IN-
TIME. In the HM arm, the implanted devices transmitted daily information
about supraventricular and ventricular tachyarrhythmias including intra-
cardiac electrograms and delivered ICD therapies; atrial tachyarrhythmia
burden; mean heart rate; the incidence of ventricular extrasystoles; pa-
tient physical activity; technical parameters such as lead impedances,
....................................................................................................................................................................................................................
Table1 Included trials
TRUST3 ECOST5 IN-TIME12
No. of centres 102 USA sites 43 French sites 26 German sites, 10 sites elsewherea
Patient eligibility Class1 indication for ICD, not
pacemaker dependent
Indication for ICD, not NYHA
class IV
Indication for ICD or CRT-D, heart failure (>_ 3
months), NYHA class II or III, LVEF <_ 35%
Primary objective To evaluate safety and efficacy of
extended IO intervals
To compare major CVAEs includ-
ing all-cause death
To compare heart failure outcomes using com-
posite (“Packer”) scoreb
Follow-up schedule
HM group IO at 3M and 15M. HM replaced
IO at 6M, 9M, and 12M
IO at 1-3M, 15M, and 27M. HM
replaced IO at 9M and 21M
IO at 12M, and in-between according to hos-
pital routine
Control group IO every 3M IO at 1-3M, then every 6M Same as in the HM group
Blinded endpoint committee No Yes Yes
aDenmark (three sites), Czech Republic (two), Israel (two), Australia (one), Austria (one), Latvia (one).
bThe score combines all-cause death, overnight hospitalization for heart failure, change in NYHA class, and change in patient global self-assessment.
CRT-D, cardiac resynchronization therapy defibrillator; CVAE, cardiovascular adverse event; ECOST, Effectiveness and cost of ICDs follow-up schedule with telecardiology;
HM, Home Monitoring; ICD, implantable cardioverter-defibrillator; IN-TIME, Influence of HM on mortality and morbidity in heart failure patients with impaired left ventricular
function; IO, in-office visit; LVEF, left ventricular ejection fraction; M, months; NYHA, New York Heart Association; TRUST, Lumos-T safely reduces routine office device fol-
low-up.
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.pacing threshold, or sensing parameters; low percentage of CRT in CRT-
D devices; and alerts to data transmission failure during a predefined
period (usually > 3 days).3,5,12
We appraised the quality of the included trials by the Cochrane
Collaboration’s tool for assessing risk of bias in five key domains: (i)
selection bias, based on the method of random sequence generation
and allocation concealment; (ii) performance bias (blinding of the pa-
tients and personnel); (iii) detection bias (blinding of outcome assess-
ment); (iv) attrition bias (incomplete outcome data, e.g. due to
patients lost to follow-up); and (v) reporting bias caused by selective
outcome reporting.18
Endpoints in the present analysis
The following seven outcome measures were defined prior to meta-
analysis: (i) all-cause death, (ii) CV death, (iii) all-cause death or any hospi-
talization, (iv) all-cause death or CV hospitalization, (v) all-cause death or
hospitalization for worsening heart failure (WHF), (vi) CV death or CV
hospitalization, and (vii) WHF death or WHF hospitalization.
Hospitalization was defined as at least one overnight admission.
All-cause death was the primary endpoint. Other endpoints served to
gain insight into the relative contribution and implications of the mechan-
isms of clinical benefit of HM. The first five endpoints are frequently used
in outcome studies with CV patients. The last two endpoints were added
to ensure sufficient number of events by combining death and hospital-
ization while remaining specific for CV and WHF categories. To focus on
the true CV morbidity caused by heart failure, ischaemia, arrhythmia, or
thromboembolism, we excluded the device and procedure-related
hospitalizations.
The all-cause mortality analysis involved all three trials. The other six
endpoints involved only ECOST and IN-TIME, in which an independent,
blinded endpoint committee adjudicated the underlying causes of hospi-
talizations and deaths.
Patients
The primary analysis populations of the TRUST, ECOST, and IN-TIME tri-
als comprised 2436 patients.3,5,12 After exclusion of 31 patients with miss-
ing study termination date, we performed the all-cause mortality analysis
on 2405 patients (Table 2). Other analyses involved 1078 (ECOST, IN-
TIME) patients.
Data management
The coordinating investigator of IN-TIME (G.H.) invited the coordinating
investigators of TRUST (N.V.), and ECOST (S.K.) to participate in this col-
laborative analysis. Anonymized patient-level data from all three trials
were compiled into a single dataset by the IN-TIME biostatistical team
and forwarded to the Department of Public Health in Copenhagen
(T.A.G.) and the Department of Clinical Epidemiology in Aalborg
(C.T.-P.) for meta-analysis. No further ethics board review was sought
for because each included study had already obtained it for the primary
publication.
Statistical analysis
The absolute risk of all-cause mortality was calculated as a function of
time during 12 months after randomization by the Kaplan-Meier
method. For other endpoints, competing risks were accounted for by
the Aalen-Johansen estimator.19 We generally preferred absolute risk
differences over hazard ratios because (i) absolute risks have a direct
interpretation for the patients, (ii) the proportional hazard assump-
tion was violated in TRUST due to intersecting mortality curves,3 and
(iii) comparison of absolute risk differences for different endpoints
allows better understanding of relationships relevant for the
interpretation of the mechanism of HM benefit. All absolute risk dif-
ferences are reported for 12 months, oriented to the shortest-
running study, IN-TIME. The corresponding 95% CIs were based on
5000 bootstrap samples per trial. To summarize results across trials,
we used the inverse variance meta-analysis and assumed a fixed effect
model. Absolute risk differences between the HM group and controls
were statistically evaluated by the Z-test. Risk ratios at 12 months are
provided for convenience, without statistical evaluation.
Baseline variables were compared across trials by the Chi-square test
(categorical data) and ANOVA (continuous data). Continuous data are
presented as mean ± SD. To assess whether any baseline variable modi-
fied the effect of HM on any endpoint, we used Cox regression stopped
after 12 months, applied on pooled ECOST and IN-TIME data (TRUST
data disallowed hazard ratio calculation). All models allowed the baseline
hazard to differ between the two studies (stratified Cox regression). For
each variable, we compared an additive model, including the variable and
the treatment group variable, with an interaction model allowing the
treatment effect to depend on the variable. P-values for the likelihood
ratio tests were calculated using the Bonferroni-Holm correction for
multiple comparisons.
.................................................................................................
Table2 Patient baseline characteristics
TRUST3 ECOST5 IN-TIME12
No. of patients we included 1327 (99.1) 414 (95.6) 664 (100)
No. of patients we excludeda 12 (0.9) 19 (4.4) 0
Age (years) 64 ± 13 62 ± 12 65 ± 9
Male gender 959 (72.3) 367 (88.6) 536 (80.7)
LVEF (%) 29 ± 10 35 ± 13 26 ± 7
NYHA classesb
I 160 (12.2) 108 (26.8) 0
II 755 (57.4) 256 (63.5) 285 (43.0)
III 393 (29.9) 39 (9.7) 378 (57.0)
IV 8 (0.6) 0 0
History of atrial fibrillation 208 (15.7) 68 (16.4) 168 (25.3)
Coronary artery disease 890 (67.1) 270 (65.2) 458 (69.0)
Hypertension 696 (52.4) 138 (33.3) 463 (69.7)
Diabetes n.a. 84 (20.3) 266 (40.1)
Medication
Beta-blocker 1046 (78.8) 288 (69.6) 608 (91.6)
ACEI or ARB 682 (51.4) 290 (70.0) 593 (89.3)
Digitalis 301 (22.7) 13 (3.1) 127 (19.1)
ICD related information
Primary prevention indication 964 (72.8) 219 (52.9) 525 (79.1)
Single-chamber ICD 562 (42.4) 291 (70.3) 0
Dual-chamber ICD 765 (57.6) 123 (29.7) 274 (41.3)
CRT-D 0 0 390 (58.7)
Randomization group
HM 901 (67.9) 211 (51.0) 333 (50.2)
Control group 426 (32.1) 203 (49.0) 331 (49.8)
Data are mean ± SD, or n (%).
Except for coronary artery disease, differences in any variable across trials were
statistically significant (P < 0.001).
aPatients with unknown date of study termination.
bNYHA class was missing in 11/11/1 (TRUST/ECOST/IN-TIME) patients.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; n.a., not available; other abbreviations as in Table 1.
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In general, we considered a P-value < 0.05 statistically significant. All
analyses were performed in R version 3.2 (R Development Core Team,
Vienna, Austria).
Results
The 2405 patients included in the meta-analysis were enrolled at 181
sites, mainly in the USA, France, and Germany (Table 1). The mean
age of the patients varied from 62 to 65 years across trials (Table 2).
The proportion of male patients ranged from 72 to 89%. The mean
left ventricular ejection fraction (LVEF) varied from 26 to 35%, and
the proportion of patients with NYHA class III/IV heart failure ranged
widely from 10 to 57%. Symptomatic heart failure was diagnosed in
89% of all patients.
Baseline characteristics differed significantly between trials for
nearly all variables listed in Table 2. The IN-TIME patients appear to
have had the highest risk of worse clinical outcome as they were
older and had a lower LVEF, more advanced heart failure symptoms,
and a higher prevalence of atrial fibrillation and hypertension than
TRUST and ECOST patients (Table 2).
Risk of bias
According to the Cochrane Collaboration’s tool, we judged all three
trials to have appropriately randomized patients and adequately con-
cealed allocation. Although it was not possible to blind investigators
and patients in any trial, we judged the associated risk of bias to be
low, given that all-cause death (primary endpoint in our meta-
analysis) is not subject to modification by the investigator’s opinion
and that causes of hospitalizations and deaths were adjudicated by
blinded boards. The only notable difference between the trials was a
higher attrition rate in TRUST (15.0% vs. 4.6% ECOST vs. 6.8% IN-
TIME), which was also inhomogeneous (13.3% HM vs. 18.8% con-
trols), suggesting better patient retention with the aid of HM.20 If the
attrition concealed endpoints, the reported clinical benefit would be
underestimated because of the larger attrition in the control group.
The risk of selective reporting is low because the included three trials
were taken from a high-ranked publication with a documented litera-
ture search strategy.13 To our best knowledge, no eligible studies
were overseen there,13 while we did not consider any study pub-
lished later. Overall, we judge the present meta-analysis to be at low
risk of bias for all key domains.
All-cause mortality
The Kaplan-Meier curve for pooled all-cause mortality is shown in
Figure 1. In the HM group, the absolute risk of death was reduced by
1.9% at 12 months (95% CI: 0.1–3.8%), which was statistically signifi-
cant (P= 0.037) (Figure 2). The relative risk (RR) of death with HM
was 0.62 (95% CI: 0.40 – 0.95). The number needed to treat (NNT)
to prevent one death at 12 months was 52 patients.
Other endpoints
All other endpoints were assessed from 1078 patients of the com-
bined ECOST and IN-TIME datasets, since TRUST had no event adju-
dication. As seen in Figure 2, the absolute risk of CV mortality was not
significantly reduced at 12 months with HM [-1.8% (95% CI: -4.1 to
þ0.4%), P = 0.11; RR = 0.51]. Likewise, the absolute risk of all-cause
mortality combined with either all-cause hospitalization [-5.0% (-11.1
toþ 1.0%), P= 0.10; RR = 0.86] or CV hospitalization [-4.1% (-9.5%
toþ 1.2%), P = 0.13; RR = 0.85] was not reduced significantly (Figures
2 and 3). In contrast, the absolute risk reduction for all-cause mortal-
ity combined with WHF hospitalization was significant [-5.6% (-9.7 to
-1.5%), P= 0.007; RR = 0.64; NNT = 18 patients] (Figures 2 and 3).
For combined CV death or CV hospitalization, the absolute risk
reduction was not significant [-3.3% (-8.7 toþ 2.0%), P = 0.22;
RR = 0.88], but for combined WHF death or WHF hospitalization, it
was significant [-4.6% (-8.4 to - 0.7%), P = 0.02; RR = 0.67; NNT = 22
patients] (Figure 2).
Patient baseline characteristics did not modify the effect of HM for
any endpoint studied (P > 0.9 for all interactions, after correction for
multiple testing).
Discussion
The main findings of the present study are that HM reduced the risk
of all-cause mortality and the risk of all-cause mortality combined
with WHF hospitalization. A less pronounced trend towards reduc-
tion in CV endpoints, such as CV hospitalization combined with all-
cause or CV mortality, appears to be driven in full by the reduction in
WHF endpoints.
The observed 1.9% absolute risk reduction for all-cause mortality
after one year (P = 0.037) is equivalent to a risk ratio of 0.62 (95% CI:
Figure 1 Time to all-cause death for pooled TRUST, ECOST,
and IN-TIME patients. The shaded areas indicate the 95% CIs. The
numbers below panel are patients at risk. The 1.9% reduction in the
absolute risk of death in the HM group was statistically significant
(95% CI: 0.1–3.8%; P = 0.037). Abbreviations: HM, Home
Monitoring; ECOST/IN-TIME/TRUST as in Table 1.
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..0.40–0.95), which closely matches the odds ratio of 0.65 (95% CI:
0.45–0.94) reported for the same three trials by Parthiban et al.13
The confirmation of this earlier result is important, because the
Kaplan-Meier method that we were able to use treats the inhomo-
geneous durations of the pooled studies (12–27 months) and cases
of early study termination correctly.13 In an attempt to explain why a
significant survival benefit was observed in the IN-TIME trial,12 and
not in TRUST3 and ECOST5 (as illustrated by the first item in
Figure 2), we compared patient baseline characteristics between the
trials, but the baseline differences did not seem to be the underlying
reason. It should be noted, however, that none of the individual trials
was designed or powered to show a survival advantage. The 95% CI
for the risk of all-cause mortality was therefore wide in each trial,
requiring a pooled analysis to increase the statistical power.
The survival benefit in the present meta-analysis is supported by a
significant reduction of the combined endpoint of all-cause mortality
and WHF hospitalization (P = 0.007; RR 0.64). This endpoint has be-
come the most widely used outcome measure in heart failure trials
due to an increasing difficulty to prove all-cause mortality benefit
alone in the setting of generally declining heart failure mortality. The
population of our study is primarily defined as an ICD population.
Yet, in conditions when 89% of patients had symptomatic heart fail-
ure, it may be expected that the population’s morbidity would be
mostly related to heart failure so that heart failure-specific endpoints
may be appropriate study outcomes. Conversely, the endpoint com-
bining all-cause mortality and hospitalization, and the endpoints com-
bining all-cause or CV mortality and CV hospitalization, were not
significantly reduced.
Figure 2 Forest plot of the absolute risk differences (in %) for all endpoints at 12 months. A negative value (reduction) is in favour of HM.
Abbreviations: CI, confidence interval; CV, cardiovascular; hosp, hospitalization; WHF, worsening heart failure; ECOST/IN-TIME/TRUST as in
Table 1.
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We also found that the composite endpoint of WHF death or
WHF hospitalization was significantly reduced in the HM group, yield-
ing a RR of 0.67 (95% CI: 0.46–0.97), which is very close to the odds
ratio of 0.63 (95% CI: 0.4 – 0.90) for worsened composite clinical
score (primary endpoint) in the IN-TIME study.12 Furthermore, the
absolute risk reduction for WHF death or WHF hospitalization was
similar in ECOST (5.4% at 1 year) and IN-TIME (3.9%) and, in the
same time, slightly higher than the absolute risk reduction for CV
death or CV hospitalization (5.2% ECOST, 1.6% IN-TIME). As WHF
events represent a subset of CV events, this implies that HM does
not influence CV endpoints other than WHF.
Although our data are not sufficient to definitively rule out a clinic-
ally meaningful effect of HM on the prevention of arrhythmic, ischae-
mic, or thromboembolic events, the assumption that its major clinical
benefit is driven by the prevention of WHF appears plausible for two
reasons: (i) WHF decompensation requires several days or even
weeks to develop, which offers time for automatic alerting and pre-
emptive intervention;11,12 and (ii) ICDs are capable of detecting and
remotely alerting to several WHF prodromal symptoms and up-
stream factors predisposing to WHF, such as the onset of atrial or
ventricular tachyarrhythmia, increased ectopic activity, low percent-
age of biventricular pacing, and change in patient activity.11,12,21 In
contrast to these slower developments, thromboembolic events and
arrhythmias typically have a sudden onset without warning pro-
dromes, whereas ST-segment elevation or depression, a potential
marker of cardiac ischaemia, was not measured by the devices used
in the trials included in this meta-analysis.
Our observation that HM exerts less or no influence on CV events
unrelated to heart failure may be the main reason why HM had a sig-
nificant effect on the primary outcome in the IN-TIME trial only (on a
composite clinical score specifically designed for patients with heart
failure) but not in ECOST (on the incidence of major CV adverse
events combined with all-cause death).5,12,16
In two of the three trials (TRUST, ECOST), patients had fewer
regular follow-up visits in the HM arm than in the control arm. It has
been generally shown that ICD patients adhere poorly to recom-
mended follow-up schedules and that this non-adherence results in
fewer regular follow-up visits and is correlated with worse out-
come.22 The clinical benefit we report from the present meta-
analysis is compelling also because it was found against a control
group treatment that was likely better than standard treatment
owing to good patient adherence.
Several non-randomized studies with other single or combined re-
mote monitoring systems reported a larger improvement in clinical
outcomes than our meta-analysis did.10,14,15 In the context of remote
monitoring of heart failure patients, it has been generally advised that
the exact properties of different remote monitoring systems must be
considered, as clinical results are not necessarily similar for different
systems.17 We suggest that the (extraordinary) benefits found in
non-randomized studies should be confirmed in adequate
randomized controlled trials. The value of prospective randomized
controlled trials in this context was underlined by the OptiLinkHF re-
sults.23 The OptiLinkHF trial randomized 1002 ICD recipients with
heart failure to remote automated pulmonary congestion alert ON
(n = 505) or OFF (n = 497). After 18 months of follow-up, there was
no significant difference between groups in the primary endpoint, a
composite of all-cause death and CV hospitalization.23 Both technol-
ogy platform and work flow seem suited to achieve measurable bene-
fit.23 Our data suggest that multiparameter, automatic, daily remote
monitoring may be superior to other platforms, but this remains
speculative in the absence of a direct comparison of different remote
monitoring systems.
Study limitations
Except for all-cause mortality and CV mortality, all other endpoints
were composite events that were not studied in this form in the ori-
ginal trials but were constructed here to investigate the underlying
mechanism of HM benefit. To keep this investigation as sensitive as
possible, different endpoints were tested without correction for mul-
tiple testing. Since most clinical events contributed to more than one
endpoint, the studied endpoints were not independent from each
other.
Figure 3 Time to occurrence of composite endpoints for pooled
ECOST and IN-TIME patients. Upper panel: Composite of all-cause
death and a CV hospitalization, excluding device related or proced-
ure-related hospitalizations. The 4.1% absolute risk reduction in the
HM group was not statistically significant (P¼ 0.13). Lower panel:
Composite of all-cause death and a hospitalization due to WHF.
The 5.6% absolute risk reduction in the HM group was statistically
significant (P¼ 0.007). For confidence intervals, see Figure 2.
Abbreviations as in Figures 1 and 2.
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We found that the trials were similar in quality, except for a higher
and asymmetric attrition rate in TRUST, which is unlikely to cause a
meaningful distortion of the main results. Eventually, the point esti-
mate of the mortality effect in TRUST is close to the meta-analysis re-
sult. Furthermore, we assumed a similar effect size in all trials and
therefore chose a fixed effect model. Although most study character-
istics were similar between trials (devices, remote monitoring system,
our endpoint assessment), study procedures differed slightly, which
might have translated into certain differences in clinical effects.
However, similar reductions of the combined endpoints in ECOST
and IN-TIME support the assumption of a common effect.
The violation of the proportional hazard assumption by the
TRUST mortality curve remains elusive. We have therefore chosen
the cumulative incidence of endpoints at 12 months as primary
result.
Conclusion
In our meta-analysis, HM with daily verification of transmission was
associated with a consistent reduction of clinically relevant endpoints.
In the IN-TIME publication,12 we promised further analysis of the
mechanism of HM benefit. The present analysis indicates that the
benefit is likely driven by prevention of heart failure exacerbation. It is
open if the results can be transferred to other remote monitoring
systems. Survival benefits observed in non-randomized registries are
promising but require confirmation in randomized controlled trials.
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